[go: up one dir, main page]

MX2009008139A - Derivdos de 2-5a y su uso como agentes anti-cancer, antivirales y anti-parasitos. - Google Patents

Derivdos de 2-5a y su uso como agentes anti-cancer, antivirales y anti-parasitos.

Info

Publication number
MX2009008139A
MX2009008139A MX2009008139A MX2009008139A MX2009008139A MX 2009008139 A MX2009008139 A MX 2009008139A MX 2009008139 A MX2009008139 A MX 2009008139A MX 2009008139 A MX2009008139 A MX 2009008139A MX 2009008139 A MX2009008139 A MX 2009008139A
Authority
MX
Mexico
Prior art keywords
analogs
methods
compounds
relates
ameliorating
Prior art date
Application number
MX2009008139A
Other languages
English (en)
Inventor
Leonid Beigelman
Lawrence Blatt
Harri Lonnberg
Original Assignee
Alios Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alios Biopharma Inc filed Critical Alios Biopharma Inc
Publication of MX2009008139A publication Critical patent/MX2009008139A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención es concerniente con los campos de química orgánica, química farmacéutica, bioquímica, biológica molecular y medicina. En particular, es concerniente con compuestos de Fórmula (I) que activa RNasaL y con el uso de los compuestos para tratar y/o mejorar una enfermedad o una condición, tal como una infección viral. (Fórmula I).
MX2009008139A 2007-01-31 2008-01-30 Derivdos de 2-5a y su uso como agentes anti-cancer, antivirales y anti-parasitos. MX2009008139A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88758307P 2007-01-31 2007-01-31
PCT/US2008/052528 WO2008095040A2 (en) 2007-01-31 2008-01-30 2-5a derivatives and their use as anti-cancer, anti-viral and anti-parasitic agents

Publications (1)

Publication Number Publication Date
MX2009008139A true MX2009008139A (es) 2009-08-12

Family

ID=39674778

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008139A MX2009008139A (es) 2007-01-31 2008-01-30 Derivdos de 2-5a y su uso como agentes anti-cancer, antivirales y anti-parasitos.

Country Status (10)

Country Link
US (1) US20080207554A1 (es)
EP (1) EP2121719A2 (es)
JP (1) JP2010518015A (es)
KR (1) KR20100014878A (es)
CN (1) CN101652378A (es)
AU (1) AU2008210411A1 (es)
CA (1) CA2676822A1 (es)
MX (1) MX2009008139A (es)
RU (1) RU2009132512A (es)
WO (1) WO2008095040A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009086201A1 (en) * 2007-12-21 2009-07-09 Alios Biopharma, Inc. 2-5a analogs and their use as anti-cancer, anti-viral and anti- paras iti c agents
WO2010108135A1 (en) * 2009-03-20 2010-09-23 Alios Biopharma, Inc. Protected nucleotide analogs
US20100331397A1 (en) * 2009-06-24 2010-12-30 Alios Biopharma, Inc. 2-5a analogs and their methods of use
CN103209987B (zh) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
AU2011305652B2 (en) 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
KR102072041B1 (ko) 2011-12-22 2020-01-31 앨리오스 바이오파마 인크. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
HK1203075A1 (en) 2011-12-22 2015-10-16 艾丽奥斯生物制药有限公司 Substituted phosphorothioate nucleotide analogs
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
PL2861611T3 (pl) 2012-05-25 2017-08-31 Janssen Sciences Ireland Uc Nukleozydy uracylowe spirooksetanu
EP3912984A1 (en) 2012-12-21 2021-11-24 Janssen BioPharma, Inc. 4'-fluoro-nucleosides, 4'-fluoro-nucleotides and analogs thereof for the treatment of hcv
RU2015148010A (ru) 2013-04-12 2017-05-15 Ачиллион Фармасютикалз, Инк. Высокоактивное производное нуклеозида для лечения hcv
PE20160658A1 (es) 2013-10-11 2016-08-05 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos
US9828410B2 (en) 2015-03-06 2017-11-28 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
EP4088725A1 (en) 2016-09-07 2022-11-16 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for the treatment of a virus from the picornaviridae family
HRP20250266T1 (hr) 2017-02-01 2025-04-25 Atea Pharmaceuticals, Inc. Nukleotid hemi-sulfat sol za liječenje virusa hepatitisa c
JP2021521118A (ja) 2018-04-10 2021-08-26 アテア ファーマシューティカルズ， インコーポレイテッド 肝硬変を伴うｈｃｖ感染患者の治療
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
CA3171648A1 (en) 2020-02-18 2021-08-26 Gilead Sciences, Inc. Antiviral compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN117120444A (zh) 2021-04-16 2023-11-24 吉利德科学公司 使用酰胺制备卡巴核苷的方法
EP4355319A4 (en) 2021-06-17 2025-01-22 ATEA Pharmaceuticals, Inc. BENEFICIAL ANTI-HCV COMBINATION THERAPY
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CN113521099A (zh) * 2021-09-10 2021-10-22 吉林大学第一医院 锌离子在抗肠道病毒ev-d68中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI347948B (en) * 2002-11-19 2011-09-01 Sankyo Co Novel 2',5'-oligoadenylic acid compositions

Also Published As

Publication number Publication date
CN101652378A (zh) 2010-02-17
EP2121719A2 (en) 2009-11-25
JP2010518015A (ja) 2010-05-27
AU2008210411A2 (en) 2009-08-27
WO2008095040A2 (en) 2008-08-07
AU2008210411A1 (en) 2008-08-07
CA2676822A1 (en) 2008-08-07
WO2008095040A3 (en) 2009-05-07
KR20100014878A (ko) 2010-02-11
US20080207554A1 (en) 2008-08-28
RU2009132512A (ru) 2011-03-10

Similar Documents

Publication Publication Date Title
MX2009008139A (es) Derivdos de 2-5a y su uso como agentes anti-cancer, antivirales y anti-parasitos.
WO2008134761A3 (en) Modification of biological targeting groups for the treatment of cancer
TN2009000291A1 (en) Inhibitors of mek
BR112012010270A2 (pt) mentisulfonilmetano (msm) para tratamento de micro-organismos resistentes a fármaco
WO2011005595A3 (en) 2-5a analogs and their methods of use
MX2009011064A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
WO2007138116A3 (de) Pharmazeutische zusammensetzung zur behandlung von virusinfektionen und/oder tumorerkrankungen durch inhibition der proteinfaltung und des proteinabbaus
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
UA105390C2 (ru) МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2008141308A3 (en) Gene expression and pain
WO2009106819A3 (en) Biological materials and uses thereof
TN2013000366A1 (en) Viral inhibitor composition for in vivo therapeutic use
EP4327874A3 (en) 3,6-disubstituted xanthylium salts
MX2012006206A (es) Preparaciones combinacion comprendiendo exosomas y corticosteroide.
ATE492639T1 (de) Multimer zur immunstimulation
MX2010004704A (es) Inhibidores macrociclicos de la ns3 serina proteasa del virus de la hepatitis c.
MY149171A (en) Treatment and prevention of influenza
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
WO2010074936A3 (en) Enzastaurin for the treatment of cancer
WO2009138146A3 (de) Neue therapeutika für die hepatitis-therapie
MY159790A (en) Highly bridged peptides from actinomadura namibiensis
EP1921136A4 (en) NUCLEIC ACID FOR TREATING OR PREVENTING IMMUNODEFICIENCY VIRUS INFECTION